Thromboprophylaxis in Patients With COVID-19
SurgeryPage Navigation
BACKGROUND
Hospitalized patients of COVID-19 are often observed to have biomarkers of hypercoagulable state with an increased chance of incidence of VTE. In response to this, CHEST issued a rapid clinical guidance for prevention of VTE by incorporating the improved evidence updated in the past 18 months.
STUDY DESIGN AND METHODS
The research focused on the question of finding the optimal approach to thromboprophylaxis in hospitalized patients. To obtain the answers MEDLINE is searched and eight randomized controlled trials and one observational study were included in the study and a meta-analysis was performed. The panel created summaries using the GRADE Evidence-to-Decision framework. Updated guidance statements were drafted, and a modified Delphi approach was used for obtaining consensus.
RESULTS
Separate guidance statements are provided for VTE prevention in hospitalized patients with acute (moderate) illness and critically ill patients in the ICU. Each of the original questions and recommendations are divided into two questions: standard prophylaxis vs therapeutic (or escalated dose) prophylaxis and standard prophylaxis vs intermediate dose prophylaxis. As a result three additional recommendations are obtained based upon higher quality evidence.
CONCLUSION
Advances in care for patients with COVID-19 have improved overall outcomes. However, incidence of VTE in those patients remains elevated. It has been recommended to provide standard thromboprophylaxis for VTE in critically ill patients, and moderately ill patients with a low bleeding risk might benefit from therapeutic heparin.
Read more such content on @ Hidoc Dr | Medical Learning App for Doctors
Recommended News For You
Recommended Articles For You
Featured News
Featured Articles
Featured Events
Featured KOL Videos
1.
Targeted radiation therapy shows near-complete response in rare sarcoma patients
2.
Dostarlimab Boosts Long-Term Survival in Endometrial Cancer
3.
Germline Profiling May Improve Risk Stratification in t-MNs
4.
Results for Prostate Cancer Are Associated With PSA Nadir 6 Months After Primary RT.
5.
Scientists call into question safety of potential new anticancer treatment
1.
Understanding Macrocytosis: Causes, Symptoms, and Treatment Options
2.
Gender-Specific Dual Antiplatelet Therapy Strategies for Women After PCI
3.
Unlocking the Mystery of Hemoglobin C Trait: A Closer Look at a Rare Blood Disorder
4.
Ferroptosis Signaling in Tumor Progression and Therapeutic Resistance
5.
Exploring New Treatment Options for Hemophilia: A Journey into the Unknown
1.
Asian Symposium on Advancement in Hematology and Oncology (ASAHO)
2.
International Cancer Conference
3.
Asian Symposium on Advancement in Hematology and Oncology (ASAHO)
4.
Asian Symposium on Advancement in Hematology and Oncology
5.
Asian Symposium on Advancement in Hematology and Oncology
1.
Management of 1st line ALK+ mNSCLC (CROWN TRIAL Update) - Part IV
2.
Navigating the Complexities of Ph Negative ALL - Part XV
3.
Clinical Insights in Hematology
4.
An Eagles View - Evidence-based discussion on Iron Deficiency Anemia- Further Talks
5.
Updates on the First Line Management of ALK+ NSCLC
Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801
Phone :
+1-415-463-3094
Email :
anishagadia@hidoc.co
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
To get started please enter your email ID
Welcome to Hidoc Dr.
Join to enhance your clinical skills and gain specialized in-depth medical knowledge